Literature DB >> 19200452

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.

Elisabeth Schuller1, Christoph S Klade, Gabriele Wölfl, Astrid Kaltenböck, Shailesh Dewasthaly, Erich Tauber.   

Abstract

The standard administration of the investigational Japanese encephalitis vaccine IC51 is 2 doses of 6 microg with a 28-day interval. This study investigated the immunogenicity of a single-immunization, high-dose regimen (1 x 12 microg) compared to the 2-injection, standard regimen to determine the immune response that one, high-dose injection can confer. The single, high-dose regimen resulted in about 60% seroconversion rate (SCR) at 10 days after administration, but it did not reach the almost 100% SCR achieved by the 2-dose standard administration at Day 35. The standard regimen conferred essentially 100% seroconversion already 7 days after the second immunization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200452     DOI: 10.1016/j.vaccine.2008.12.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review.

Authors:  Xing Li; Shu-Juan Ma; Xie Liu; Li-Na Jiang; Jun-Hua Zhou; Yi-Quan Xiong; Hong Ding; Qing Chen
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  Product review on the JE vaccine IXIARO.

Authors:  Christa Firbas; Bernd Jilma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Statement on Protection Against Japanese Encephalitis: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT)* †.

Authors:  M Tepper; Dr S Schofield
Journal:  Can Commun Dis Rep       Date:  2011-04-08

4.  Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain.

Authors:  Amanda E Calvert; Kandice L Dixon; Mark J Delorey; Carol D Blair; John T Roehrig
Journal:  Vaccine       Date:  2013-11-17       Impact factor: 3.641

5.  New vaccines for Japanese encephalitis.

Authors:  Scott B Halstead; Stephen J Thomas
Journal:  Curr Infect Dis Rep       Date:  2010-05       Impact factor: 3.725

Review 6.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

Review 7.  Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis.

Authors:  Shi-Yuan Wang; Xiao-Hua Cheng; Jing-Xin Li; Xi-Yan Li; Feng-Cai Zhu; Pei Liu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Japanese Encephalitis Vaccines.

Authors:  Monica A McArthur; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011-09-25

9.  Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO®).

Authors:  D Amicizia; F Zangrillo; P L Lai; M Iovine; D Panatto
Journal:  J Prev Med Hyg       Date:  2018-03-30

10.  Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO].

Authors:  Sean T Duggan; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.